Molecular Health at ESMO 2018

Описание: Held under the tagline “Securing access to optimal cancer care”, the ESMO 2018 Congress took place between 19 and 23 October in Munich, Germany.

Recent years have seen an enormous increase in the generation of data in healthcare. Such data includes information on the genetic alterations of cancer, with the potential for using such alterations as biomarkers for the early detection and monitoring of specifi c cancers, as well as to design individualised treatments. Data collected may also include patient characteristics and germline pharmacogenomic markers, which provide information on drug metabolism and availability at the target site.1 Repositories of these data facilitate the construction of models that predict the outcome of different treatments—including drug-induced adverse events—and therefore the prospect of providing precision medicine based on the genetic characteristics of a patient and their tumour.

While collecting data is all very well and good, the essential aspects of big data are in its analysis and the interpretation of fi ndings. Considering the huge amount of data available and the enormity of the task of integrating patient and genetic characteristics with treatments and outcomes, it is no surprise that machine learning and artifi cial intelligence have emerged as unique means of deciphering such complex and vast information. Maintaining patient confidentiality and the legal implications of data sharing are key considerations, but existing regulation and technology are aligned in order to guarantee anonymisation and patient privacy. MH Guide is the first software registered in Europe as an in vitro diagnostic medical device for analyzing and interpreting tumors. It is continuously optimized by means of clinical validation in studies as well as intense client contact to highly regarded cancer centers in multiple countries.

Molecular Health GmbH is DIN EN ISO 13485 certified for the scope Design, Development and Manufacture of software systems for the integrated analysis of clinical and genomic patient data to support treatment decisions and provisioning of related services.